News

EMA Reverses Opinion on Delamanid for MDR-TB

Source: European Medicines Agency http://www.ema.europa.eu

On 21 November 2013, the Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional marketing authorisation for the medicinal product Deltyba for the treatment of lung infections due to multidrug-resistant tuberculosis when alternative treatments cannot be used due to resistance or intolerance. The company that applied for authorisation is Otsuka Novel Products GmbH.

On 25 July 2013, the CHMP had originally adopted a negative opinion for Delamanid in multidrug-resistant tuberculosis. At the request of the applicant, the CHMP started a re-examination of its opinion. Following the re-examination, the CHMP adopted a final positive opinion on 21 November 2013 recommending the granting of a conditional marketing authorisation for Deltyba, but restricting its use to treatment of tuberculosis affecting the lungs and to situations where alternative treatments cannot be used due to resistance or intolerance. Click here to to download the news release from EMA.

Additional Coverage:

CHMP Recommends Otsuka’s Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)

Tuberculosis Drug Wins Backing of European Panel (WSJ)

View Delamanid on Global Pipeline–http://www.newtbdrugs.org/project.php?id=136

More News
23 Aug 2022
Last week, the PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...